Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Chile | Pakistan
Approved Indications: None
Known Adverse Events: None
Company: Universitaire Ziekenhuizen KU Leuven
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Obesity
Phase 3: Colorectal Cancer
Phase 1: Type 2 Diabetes|Obesity
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2500110026 |
ChiCTR2500110026 | N/A |
/Completed |
Alcoholism |
2025-08-31 |
|||
ChiCTR2300071590 |
ChiCTR2300071590 | N/A |
Not yet recruiting |
Alcoholism |
2025-06-30 |
2023-06-11 |
Treatments |
|
NCT05562713 |
Pro00111134 | N/A |
Completed |
Urinary Bladder, Neurogenic|Spinal Dysraphism |
2024-04-18 |
2024-06-07 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT05070442 |
DINE | N/A |
Completed |
Obesity|Communicable Diseases|Acute Respiratory Distress Syndrome|Weight Loss |
2022-10-26 |
2023-02-16 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
ACTRN12622000389707 |
MM-BP | N/A |
Completed |
Depressive Disorder |
2022-04-10 |
2026-02-06 |
Treatments |
|
NCT05010291 |
NCT05010291 | N/A |
Completed |
Acquired Immunodeficiency Syndrome|HIV Infections |
2021-12-07 |
2022-07-21 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
ACTRN12620001193965 |
ACTRN12620001193965 | N/A |
Recruiting |
COVID-19 |
2020-11-30 |
2024-11-19 |
Treatments |
|
NCT03338829 |
NCT03338829 | N/A |
Completed |
Pregnancy in Diabetics|Diabetes, Gestational|Pregnancy Outcomes |
2019-12-18 |
2025-07-31 |
Primary Endpoints |
|
NCT02890459 |
IBIS-Health | N/A |
Completed |
HIV Infections |
2019-08-21 |
2020-02-19 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT03777787 |
S61251 | N/A |
Completed |
Gastroesophageal Reflux |
2019-05-10 |
2022-09-27 |
Primary Endpoints|Treatments |
|
NCT03375541 |
DRAC | N/A |
Withdrawn |
Multiple Sclerosis |
2019-03-01 |
2019-03-21 |
Treatments |
|
ACTRN12618001098224 |
ACTRN12618001098224 | N/A |
Completed |
Colorectal Cancer |
2017-07-12 |
2024-08-29 |
Treatments |
|
ACTRN12616000026426 |
ACTRN12616000026426 | N/A |
Completed |
Type 2 Diabetes |
2016-10-11 |
2024-08-29 |
Treatments |
|
ACTRN12615001191583 |
ACTRN12615001191583 | N/A |
Not yet recruiting |
Acute Pain|Neuropathic Pain|Colorectal Cancer|Brain Cancer|Back Pain|Glioma |
2015-11-19 |
2024-08-29 |
Treatments |
|
NCT02759926 |
BitterMotilityHungerFoodIntake | N/A |
Unknown status |
Obesity |
2015-11-01 |
2022-09-27 |
Primary Endpoints|Treatments |
|
ACTRN12611000960954 |
ACTRN12611000960954 | N/A |
Recruiting |
Dehydration |
None |
2024-08-29 |
Patient Enrollment|Treatments|Trial Status |
|
ACTRN12618001764224 |
ACTRN12618001764224 | P1 |
Completed |
Obesity|Type 2 Diabetes |
2018-02-01 |
2024-08-29 |
Treatments |
|
ACTRN12624000377538 |
ACTRN12624000377538 | P1 |
Recruiting |
Type 2 Diabetes|Obesity |
None |
2026-01-27 |
Treatments |
|
ACTRN12607000461493 |
ACTRN12607000461493 | P3 |
Not yet recruiting |
Colorectal Cancer |
None |
2024-11-19 |
Treatments |
|
NCT03985865 |
IG vs ID | P4 |
Completed |
Obesity |
2018-05-07 |
2022-09-27 |
Primary Endpoints|Treatments |